ArticleLeukemia2019

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

Olivier Humbert et al.PubMed ↗Publisher ↗

No numbers read from the abstract.